<DOC>
	<DOCNO>NCT00930839</DOCNO>
	<brief_summary>This study focus investigate nicotinic acid stimulate release prostaglandin D2 normal control . In subsequent study , investigator would like explore pathway people type 2 diabetes . Enhanced blood flow ( flush ) may compromise exaggerated type 2 diabetes particularly impairment autonomic function measure respiratory heart rate variability ( HRV ) different frequency reflect balance sympathetic parasympathetic nervous system . The investigator hypothesize vasodilatory effect induce nicotinic acid different glabrous hairy skin autonomic imbalance may alter response .</brief_summary>
	<brief_title>Role Prostaglandins Niacin-Induced Flushing</brief_title>
	<detailed_description>The investigator propose nicotinic acid ( NA ) stimulate release prostaglandin D2 ( PGD2 ) . To fully understand mechanism , investigator examine systemic release PGD2 skin blood flow use laser Doppler ( LDF ) upper low limb healthy control subject . The investigator quantify establish effect oral nicotinic acid ( NiaspanÂ® ) give alone combination aspirin : 1. skin blood flow use laser Doppler ( LDF ) glabrous hairy skin forearm healthy subject 2. severity intensity flush use visual analog scale , FAST tool , whether aspirin able block flush response 3. impact sympathetic/parasympathetic balance use various frequency heart rate variability ( HRV ) reflect contribution different division autonomic nervous system ( ANS ) 4. circulating level PGD2 neuropeptides determine mediator flush response . This allow u conclude whether pathway intact explore non-DP1 vasodilatory mechanism . 5 . Langerhans cell density epidermis microvasculature use immunohistochemistry Langerin ( measure CD1a ) 3 mm skin biopsy volar hairy surface forearm hairy surface lateral aspect proximal low limb . To date , little known density distribution Langerhans cell . The PGD2 receptor DP1 examine content epidermis use immunohistochemistry RTPCR .</detailed_description>
	<mesh_term>Flushing</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Healthy control age 3080 1 . Presence type 1 diabetes type 2 diabetes 2 . Presence clinically significant neuropathy , ( Dyck stage &gt; 2b ) define abnormal neurologic testing ( neurologic physical exam , nerve conduction , autonomic quantitative sensory test ) 3 . History major macrovascular event myocardial infarction stroke within past 3 month 4 . Participation another clinical trial concurrently within 30 day prior entry study . 5 . Uncontrolled untreated hypothyroidism evidence TSH concentration &gt; 4.8 uU/ml 6 . Other serious medical condition , opinion investigator , would compromise subject 's participation study , include sensitivity aspirin 7 . Abnormalities liver function define liver enzymes ( AST , ALT , SGPT , SGOT ) great 3 time upper limit normal 8 . History NYHA Class IV congestive heart failure . 9 . Allergy Niaspan aspirin 10 . Use drug know affect prostaglandin metabolism angiotensin convert enzyme inhibitor ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) allow stable use 3 month . 11 . Pregnancy breastfeed 12 . History peptic ulcer disease 13 . Current history smoking</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Niacin</keyword>
	<keyword>Prostaglandin D2</keyword>
	<keyword>Flushing</keyword>
	<keyword>Nicotinic acid stimulate release prostaglandin D2</keyword>
</DOC>